Lannion,
REVENUES FOR THE FIRST 9 MONTHS OF 2023: €139.0M (+11%)
- Continued growth for both divisions at constant exchange rates
- Strong level of activity expected in Q4
Consolidated revenues (unaudited)
Revenues (€m) | 2023 | 2022 | Reported change | Change at constant scope and exchange rates |
First quarter | 40.9 | 38.0 | +8% | +9% |
Second quarter | 56.3 | 46.0 | +22% | +25% |
Third quarter | 41.8 | 40.9 | +2% | +5% |
9 months* | 139.0 | 124.9 | +11% | +13% |
of which | ||||
Photonics* | 65.9 | 58.2 | +12% | +15% |
Medical | 73.0 | 66.7 | +9.5% | +12% |
* Including revenues of Convergent, acquired on 31 August, representing €0.7m in September.
By Market Segment
Over the first 9 months, the Photonics division grew by +13% (+15% like-for-like and at constant exchange rates) compared with the first 9 months of 2022, with €20m in the third quarter (+2% and +3% like-for-like and at constant exchange rates).
The Defence/Space segment is up +32% in the third quarter at €6.9m, on a -like-for-like basis, as the
After the strong growth in H1, the Lidar segment recorded a temporary decline in sales in the third quarter (-24% at €4.1m), although business remains buoyant, with growth of 11% to €18.3m over the first 9 months.
The Industrial and Scientific activities are stable in Q3 (+1% at €9.1m), with 9-month sales, down 8% at €23.9m, still affected by capacity restrictions at the start of the year.
The Medical division, meanwhile, posted sales of €21.8m in the 3rd quarter (+2% and +6% at constant exchange rates). Over 9-months, sales grew by 9% to €73.0m (up 12% at constant exchange rates). The division's sales are split between diagnostics (25%) and treatment (75%). This growth was driven by new product launches in several market segments and marketing authorisations in new geographical areas.
By Geography
The breakdown of 9 months sales by division and by geographical area is as follows:
Revenues (€m) | Photonics | Chg. | Medical | Chg. |
EMEA | 33.5 | +29% | 23.9 | +20% |
12.7 | -1% | 20.4 | -5% | |
15.0 | +24% | 18.6 | +11% | |
ROW | 4.7 | -36% | 10.1 | +19% |
Total | 65.9 | +13% | 73.0 | +9% |
Unaudited data
Strong growth in the Photonics division in
The Medical division's sales for the first 9 months of the year were similar to those recorded in H1, with strong growth in
With seasonality favouring business at the end of the year, a strong order book and production facilities at full capacity,
The Group can therefore maintain its target for 2023 of organic sales growth of at least 8%, based on the scope at
Born from the combination of
Since 2022,
Contacts
Chairman and CEO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Chief Financial and Transformation Officer Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Calyptus Investors Relations Tel. +33(0) 1 53 65 37 91 lumibird@calyptus.net |
Attachment
- 231024_Lumibird_CAQ3_2023EN
© OMX, source